Biotechnology

Margaret Mitchell explores how a German biotech's moss-grown protein could shift the paradigm in complement-mediated diseases from inhibition to restoration.

With a $50B market in play, NFL Biosciences is leveraging predictive biomarkers and novel neurobiology to disrupt the stagnant smoking cessation landscape.

As Peptides Canada launches its domestic supply platform, we explore the regulatory tightrope and supply chain dynamics reshaping the nation's biotech landscape.

Vaxcyte is arming itself with $1 billion in fresh capital to challenge Pfizer and Merck, leveraging a dual-tranche financing strategy to scale manufacturing.

Equillium's Phase 1 trial of EQ504 in Australia signals a strategic shift in ulcerative colitis care, prioritizing targeted mucosal healing.

The 2026 Nobel Prize in Medicine honors three scientists who turned light into a neurological remote control, paving the way for revolutionary clinical therapies.

Exthymic's ARPA-H contract aims to decentralize cell therapy manufacturing, leveraging adaptive phenotyping to bypass centralized cleanrooms.

With Phase 3 enrollment complete, vTv Therapeutics aims to succeed where pharmaceutical giants failed in the quest for a Type 1 diabetes pill.

With new Canadian government funding, Vasomune Therapeutics is reformulating its vascular leak drug for the frontlines of military and civilian trauma.

Coave Therapeutics is leveraging AI and novel suprachoroidal delivery to disrupt the wet AMD market, targeting the end of chronic eye injections.

Ajinomoto Bio-Pharma Services' latest rebrand signals a vital shift, prioritizing deep technical mastery in complex therapies over the one-stop-shop model.

Antengene’s novel masked CD2 costimulatory platform aims to solve immunotherapy's biggest bottleneck: cytokine toxicity and systemic overheating.

Cuprina Holdings is acquiring a seven-clinic healthcare group in Singapore, transforming the biomedical developer into a vertically integrated care provider.

JCR Pharmaceuticals and Italfarmaco are teaming up to bring a revolutionary, brain-penetrating Hunter syndrome therapy to Western markets.

NORD's latest $145,000 seed funding proves that in the overlooked world of rare diseases, modest philanthropic grants are the ultimate catalyst for innovation.

Biotech challengers are leveraging gene therapy and oral molecules to dismantle the legacy infusion model in the $1.7 billion Fabry disease market.

BioCardia’s revised FDA submission for its Helix catheter could set a new regulatory standard and unlock lucrative biopharma partnerships.

PolyPid has regained European rights to its promising infection-fighting drug. Now begins a high-stakes race to secure a partner before approval.

ViroMissile's intravenously delivered oncolytic virus, IDOV-2, shows early signs of stable disease in Phase I, hinting at a breakthrough for metastatic cancers.

Taysha Gene Therapies leverages novel auto-regulatory technology and a strategic regulatory playbook to pioneer a breakthrough gene therapy for Rett syndrome.